Cargando…
B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?
T cells play a vital role in the immune responses against tumors. Costimulatory or coinhibitory molecules regulate T cell activation. Immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have shown remarkable benefits in patients with var...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044412/ https://www.ncbi.nlm.nih.gov/pubmed/33869045 http://dx.doi.org/10.3389/fonc.2021.647526 |
_version_ | 1783678478995947520 |
---|---|
author | Zhang, Wei Qiu, Yu Xie, Xiaoli Fu, Yao Wang, Lijuan Cai, Zhen |
author_facet | Zhang, Wei Qiu, Yu Xie, Xiaoli Fu, Yao Wang, Lijuan Cai, Zhen |
author_sort | Zhang, Wei |
collection | PubMed |
description | T cells play a vital role in the immune responses against tumors. Costimulatory or coinhibitory molecules regulate T cell activation. Immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have shown remarkable benefits in patients with various tumor, but few patients have displayed significant immune responses against tumors after PD-1/PD-L1 immunotherapy and many have been completely unresponsive. Thus, researchers must explore novel immune checkpoints that trigger durable antitumor responses and improve clinical outcomes. In this regard, other B7 family checkpoint molecules have been identified, namely PD-L2, B7-H2, B7-H3, B7-H4 and B7-H6. The aim of the present article was to address the expression, clinical significance and roles of B7 family molecules in lymphoma, as well as in T and NK cell-mediated tumor immunity. B7 family checkpoints may offer novel and immunotherapeutic strategies for patients with lymphoma. |
format | Online Article Text |
id | pubmed-8044412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80444122021-04-15 B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy? Zhang, Wei Qiu, Yu Xie, Xiaoli Fu, Yao Wang, Lijuan Cai, Zhen Front Oncol Oncology T cells play a vital role in the immune responses against tumors. Costimulatory or coinhibitory molecules regulate T cell activation. Immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have shown remarkable benefits in patients with various tumor, but few patients have displayed significant immune responses against tumors after PD-1/PD-L1 immunotherapy and many have been completely unresponsive. Thus, researchers must explore novel immune checkpoints that trigger durable antitumor responses and improve clinical outcomes. In this regard, other B7 family checkpoint molecules have been identified, namely PD-L2, B7-H2, B7-H3, B7-H4 and B7-H6. The aim of the present article was to address the expression, clinical significance and roles of B7 family molecules in lymphoma, as well as in T and NK cell-mediated tumor immunity. B7 family checkpoints may offer novel and immunotherapeutic strategies for patients with lymphoma. Frontiers Media S.A. 2021-03-31 /pmc/articles/PMC8044412/ /pubmed/33869045 http://dx.doi.org/10.3389/fonc.2021.647526 Text en Copyright © 2021 Zhang, Qiu, Xie, Fu, Wang and Cai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhang, Wei Qiu, Yu Xie, Xiaoli Fu, Yao Wang, Lijuan Cai, Zhen B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy? |
title | B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy? |
title_full | B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy? |
title_fullStr | B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy? |
title_full_unstemmed | B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy? |
title_short | B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy? |
title_sort | b7 family members in lymphoma: promising novel targets for tumor immunotherapy? |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044412/ https://www.ncbi.nlm.nih.gov/pubmed/33869045 http://dx.doi.org/10.3389/fonc.2021.647526 |
work_keys_str_mv | AT zhangwei b7familymembersinlymphomapromisingnoveltargetsfortumorimmunotherapy AT qiuyu b7familymembersinlymphomapromisingnoveltargetsfortumorimmunotherapy AT xiexiaoli b7familymembersinlymphomapromisingnoveltargetsfortumorimmunotherapy AT fuyao b7familymembersinlymphomapromisingnoveltargetsfortumorimmunotherapy AT wanglijuan b7familymembersinlymphomapromisingnoveltargetsfortumorimmunotherapy AT caizhen b7familymembersinlymphomapromisingnoveltargetsfortumorimmunotherapy |